Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.
about
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its ComorbiditiesFibroblast growth factor 23Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease?Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular DiseaseNovel biological markers of bone: from bone metabolism to bone physiologyThe Role of Emerging Risk Factors in Cardiovascular OutcomesPotential pathophysiological role for the vitamin D deficiency in essential hypertension.Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4S100/Calgranulin-mediated inflammation accelerates left ventricular hypertrophy and aortic valve sclerosis in chronic kidney disease in a receptor for advanced glycation end products-dependent mannerFGF23 protein expression in coronary arteries is associated with impaired kidney function.Vascular calcification in chronic kidney disease: role of disordered mineral metabolism.αKlotho and vascular calcification: an evolving paradigm.FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability.A current understanding of vascular calcification in CKD.Association of fibroblast growth factor-23 with arterial stiffness in the Multi-Ethnic Study of AtherosclerosisActive vitamin D and accelerated progression of aortic stiffness in hemodialysis patients: a longitudinal observational study.Implications of Klotho in vascular health and disease.Serum fibroblast growth factor-23 is associated with incident kidney disease.Soluble Klotho is not independently associated with cardiovascular disease in a population of dialysis patientsA low fractional excretion of Phosphate/Fgf23 ratio is associated with severe abdominal Aortic calcification in stage 3 and 4 kidney disease patients.Fibroblast growth factor 23 and risk of incident stroke in community-living adultsFGF-23 associated with the progression of coronary artery calcification in hemodialysis patients.Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease.The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic kidney disease.Capillary rarefaction: an early marker of microvascular disease in young hemodialysis patients.Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid, and aorta of uremic rats.Serum Phosphorus Concentration and Coronary Artery Calcification in Subjects without Renal DysfunctionEpidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease.Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.Fibroblast Growth Factor 23 Is Associated With Carotid Plaque Presence and Area: The Northern Manhattan Study.The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease.High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis.Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014The Role and Mechanism of α-Klotho in the Calcification of Rat Aortic Vascular Smooth Muscle Cells.Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus.Skeletal Muscle, but not Cardiovascular Function, Is Altered in a Mouse Model of Autosomal Recessive Hypophosphatemic Rickets.Phosphate Toxicity in CKD: The Killer among UsAssociations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure.Preclinical Pharmacokinetics, Pharmacodynamics and Safety of Sucroferric Oxyhydroxide.
P2860
Q26798487-124FE984-6842-409F-B784-5D6D32340811Q26829294-E84F9FC5-8601-4075-8AFE-FEBB773B5421Q27002431-60BB958D-6999-4228-ADB6-7FE395248A20Q27024043-388FC568-2178-46A7-97DE-4D3F29348BB8Q28067712-2C10A829-9645-4CA2-8158-641082D8B880Q30234550-DBB943E7-ED7B-436A-9673-69664E2E3328Q30363752-647B5C46-3E36-4C08-9A1A-2C413AF5A4B2Q33715785-A48D8085-166A-46A4-8FB5-01DF5569EC40Q33939707-574C7029-1762-4083-8928-DBB5AAF1706FQ33985430-DE0F8BA3-7272-4FDA-8212-AF0AB32A2A65Q34037021-E4A48C0D-F26C-4FD8-979F-EDB6019C763FQ34078872-26E30218-490E-4568-A6C8-637C90D7498BQ34130840-E760DFBE-3ADC-445D-9C98-EC046BED103BQ34355897-AE594BC7-6DF8-416D-8D7D-3FA89488784BQ34406871-73852537-02D2-4CD3-8619-F02B7DF75C71Q34683694-4142A348-F086-4278-BA12-CF062E9BA32BQ34780123-C351A13D-BFAB-4EDD-BD00-67421B6D30C0Q34787817-34864DA5-DED7-4D45-B2D0-126E06C3AEA5Q34941418-A11E81E6-8EB6-4B53-93A3-8BADAA2005A0Q35015899-77F23F6C-36A6-4517-BC06-DA1BC5A2ADA9Q35019943-7C596530-7348-4D74-922D-F75142AE6CADQ35030290-A10859A2-37B3-4E51-886C-5F2D69DDAA99Q35153209-938BF629-8F27-4F4F-816F-89ECC719FCBBQ35218508-3FB9E7F7-4EE8-44F9-BC42-DD87F37B8676Q35310636-7D1A675C-7D0B-43A5-9C74-BEA27C6354F1Q35667633-A70F6320-708C-49C4-BC08-F6D8E75B5FAAQ35963073-2A9D2212-ED86-491D-940A-D032680175E1Q35997370-17CBDE64-4259-4C25-8ADE-BB9FA74A4910Q35998095-003C9FD0-05D3-4C1B-9963-ED705E266A8FQ36004493-9AEA05C9-B34F-4652-9800-553625684FCCQ36098749-9495529F-50E8-44C1-839C-9DB71499A74DQ36104814-7EA3F51E-AF38-4BFE-846F-53D06AF19885Q36104887-5951B8DF-DA6C-4FF8-B609-15C34A8E7F14Q36123640-BDC23BBF-46A9-4064-B27F-2E3B2B24DF3DQ36280036-1CE4F311-D770-41FB-A1AB-5DAF90E38E66Q36520483-4D2B8C92-A8E7-4524-B851-AA9DAE2EB57BQ36899883-B1D49DF6-BB9E-492B-B358-93FC4B02717DQ36965142-C724C645-8CB8-4AF7-8EE7-F0E26BFAEDF8Q37126261-3A6A4638-D1C2-4457-8717-D52E38B23CA8Q37204047-F01E2403-451C-4FEF-94A3-A0041CD3B0BC
P2860
Fibroblast growth factor 23 is not associated with and does not induce arterial calcification.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Fibroblast growth factor 23 is ...... induce arterial calcification.
@en
type
label
Fibroblast growth factor 23 is ...... induce arterial calcification.
@en
prefLabel
Fibroblast growth factor 23 is ...... induce arterial calcification.
@en
P2093
P2860
P356
P1433
P1476
Fibroblast growth factor 23 is ...... induce arterial calcification.
@en
P2093
Ansel P Amaral
Boyang Chai
Cecilia M Giachelli
Chronic Renal Insufficiency Cohort Study Investigators
Hsueh-Ying Yang
James P Lash
John W Kusek
Julia J Scialla
P2860
P2888
P304
P356
10.1038/KI.2013.3
P407
P577
2013-02-06T00:00:00Z